Home › Multilingual Archive Index › 3,4-Diaminopyridine

3,4-Diaminopyridine

3,4-Diaminopyridine is an experimental drug used in the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca²⁺ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca²⁺ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate.

It has also been proposed for use in multiple sclerosis.^[3]

See also

• 4-Aminopyridine

References

1. ^ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve 24: 1236–1238. doi:10.1002/mus.1139. 
2. ^ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.". Acta Neurol Scand 88: 136–140. 
3. ^ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID 16472864.